Appili announces dosing of first patient in phase 3 Covid-19 trial
PRA Health Sciences, a clinical research organisation (CRO) selected by Appili, will conduct the trial at 47 outpatient sites. Avigan, which is an antiviral in oral tablet form
1n 2019, Astellas and FibroGen have also received Japanese approval for roxadustat for the treatment of anaemia in adult patients with CKD and on dialysis. FibroGen now secures